Digital Health Centre of Excellence



TechNet-21 The Technical Network for Strengthening Immunization Services

#### October 25, 2022

# An Introduction to CommCare & Jamaica Use Case

Jordan Lerner, Dimagi, Senior Project Manager

Denese Palmer, Ministry of Health and Wellness, Jamaica, Director, ICT Unit (Acting)

Albert Beckford, Ministry of Health and Wellness, Jamaica, Application, Infrastructure, and Integration Technical Lead

# Webinar Format



- An overview of CommCare
- A use case from Jamaica
- Q&A

# Dimagi & CommCare

- Introducing Dimagi and CommCare
- Overview: Dimagi Vaccine Solution
- Table of functional requirements
- Considerations for implementation support
- Typical implementation timelines
- Contracting options
- Cost Considerations



## Hello!



Jordan Lerner Senior Project Manager Dimagi

# Who We Are



An award-winning social enterprise founded in 2002 out of MIT and Harvard Medical School that supports frontline workers with innovative technology

On a mission to create sustainable impact for underserved populations through innovative technology solutions for frontline workforces

### ₽₩

#### 180+ Members

Dimagi's staff is based in offices in the United States (HQ), India, South Africa, and Ethiopia.

#### 2,000+ Projects

We've supported thousands of projects in diverse sectors.



#### 130+ Countries

Dimagi has supported projects in more than 130 countries across six continents.

# Introducing CommCare



**400 million** People Registered



**130+** Countries 2000+ Projects The most widely-used open source, offline data collection and service delivery platform—built for the last mile<sup>1</sup>



**Global Digital Good**<sup>2</sup> An established global good that has already been deployed in multiple countries



#### Effective for COVID-19 Response<sup>3</sup>

Recognized for turn-key ready applications for COVID-19 and a history of proven success with large scale deployments

#### Evidence Based<sup>4</sup>

75+ peer-reviewed studies have been conducted exploring CommCare's impact on frontline programs globally



### **CommCare Key Features**

Ð

Works offline

Seamless workflows for end users without internet connectivity



Multilingual Local language application translations and data capture



**Open Source** Open source platform with free training tools and a community of CommCare users




Multimedia

Images, audio, and videos support low-literacy users with application navigation



## CommCare for COVID-19 Vaccine Delivery



Registration, Screening & Dose Delivery Dose and UID Confirmation & Self Reporting of Adverse Events

Tracking Missed Doses and Appointments Administer Follow Up Dose & Course Completion

Monitor Vaccine Campaign

### **Problem Statement**

The COVID-19 pandemic has disrupted the delivery of routine immunizations, leaving communities vulnerable to the emergence of vaccine preventable diseases<sup>5</sup>.

# More children missed out on routine immunizations in 2020 than in 2009<sup>1</sup>

- Immunizations are highly successful and costeffective public health tools<sup>2</sup>
- Vaccines are available for the **prevention of 25 diseases**, with 15 more in development<sup>3</sup>
- Globally, they are responsible for a consistent decline in deaths that can be wholly or partially prevented through vaccination<sup>4</sup>

## Communities are vulnerable to vaccine preventable diseases<sup>5</sup>

- Disruptions in routine immunization due to COVID-19 can lead to secondary health crises<sup>5</sup>
- Unvaccinated individuals are susceptible to vaccine preventable diseases such as measles and rubella<sup>5</sup>
- The risks are particularly acute for children; in 2020, 23 million children missed out on basic vaccines<sup>1</sup>

<u>dåmag</u>i

### The Solution

There is a need to maintain our focus on the equitable delivery of COVID-19 vaccines while also restoring previous rates of routine immunization.

The Dimagi Vaccine Solution equips countries with tools to make progress on both COVID-19 and routine immunization in parallel, without one happening at the cost of the other.

| 8:31                               | (2) 북동 종, <sup>Voo</sup> , 111章  |  |  |
|------------------------------------|--|--|--|
| 🗧 Dimagi Vaccine                   | Solution   |  |  |
| <b>.</b>                           |  |  |  |
| Register and View<br>Households    | Register and View<br>Clients   |  |  |
| ۰                                  | ŀ  |  |  |
| Children and<br>Adolescents        | Pregnant Women   |  |  |
|                                    | Benug Vochris fundament<br>Benug Vochris fundame | Annu frank Najeran (15 tao     12144     12144   | energi dana eta al   |
| 🔨 🌂 🏥                              | **2.0 Kind water Hank  | Contract of the states  | -2.03 2.03 20.000  |
| Clients Due for<br>Follow-Up Visit | and the  |  | 40         -10           42         -20           42         -20           43         -20           44         -20           45         -20           46         -20           46         -20           46         -20           47         -20           48         -20           49         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20           40         -20 |
| <b>9</b> !                         | V  | Norman         0           Norman         0 |  |
|                                    |  |  |  |
|                                    |  |  |  |
|                                    |  |  | <u>dåmag</u> i   |


### **Modular Application Design**


Six micro-applications – each designed for a different immunization challenge:



Partners can select and configure each micro-application based on local requirements.

### **Core Solution Components**








Mobile and Web Application Frontline Workers Messaging Direct to Clients Analytics Government Stakeholders

### Client Registry



#### APPLICATION AND MESSAGING

- Register households/clients at a facility, with the option to capture touchless biometrics at the time of registration
  - Clients can register remotely using SMS or WhatsApp

Record historical vaccination data

#### DASHBOARD AND INTEGRATIONS


4

2

3

Integrate with national birth registries to ensure that children receive timely reminders for routine immunizations

#### Vaccine Delivery



#### APPLICATION AND MESSAGING

- Configure vaccine schedules according to global and local guidelines
- Administer vaccine doses and send clients automated 2 reminders for follow-up appointments
  - Integration with IVR service to make appointment reminder and follow up calls


#### DASHBOARD AND ANALYTICS

3

4

Analyze immunization completion and dropout rates

### Adverse Events Following Immunization



#### APPLICATION AND MESSAGING

- Report adverse events at the facility or through client messaging channels
  - Workflow for health officials to investigate adverse events
  - Integration with IVR service to make appointment follow up calls and enable call-based AEFI reporting

#### DASHBOARD AND ANALYTICS


4

2

3

View reports of adverse events following immunization by vaccine type and client category

# Community Mobilization & Counseling



#### APPLICATION AND MESSAGING

Vaccine confidence counseling to increase vaccine uptake

Course completion tracking and follow up

#### DASHBOARD AND ANALYTICS

3

4

2

View the number of community events organized and participant details

Analyze vaccine hesitancy rates and reasons reported for vaccine hesitancy

### Health Worker Training

| 5:57  | 10 NI S-111                 |
|---|-----------------------------|
| ← Introduction to Vaccines  | 1                           |
| <   | >                           |
| Education > Functions of V  | /accines                    |
| Vaccines Work?  | How do                      |
| ase agents and stimulating the<br>une system to build up a defen-<br>net them.<br>mmune system protects the<br>from pathogens, which are<br>ts that can cause disease.<br>ccine is like a pathogen-impost<br>ks like a certain bacteria or vir<br>e immune system but doesn't<br>to the body sick<br>ogens are covered with<br>cules called antigens that can<br>er a specific immune response<br>ination exposes the body to<br>ens that are similar to the<br>ens found on a pathogen,<br>soing as a specific pathogen, the<br>primes the immune system<br>spond with speed and strength<br>ody encounters the pathogen<br>sture. | ce<br>ter:<br>us<br>he<br>i |


#### APPLICATION AND MESSAGING

2

In-app and WhatsApp training on vaccine related topics for health care workers

Access to open source course content created by WHO

### Facility Management & Stock Monitoring



#### APPLICATION AND MESSAGING

Facility registration and preparedness assessments

Basic reporting on stock availability and logistics

#### DASHBOARD AND ANALYTICS

2

3

4

Wastage of vaccine doses

Stockouts of vaccines and other critical supplies

# **Key Program Indicators**

| ter by State                                   | 0 :   | Pitter by District       | 0 :  | Filter by Vaccination Cent<br>vaccounter central | 19                               |                      | 0    |
|--|---|--------------------------|--|--|----------------------------------|----------------------|------|
| 'ype or Solicet (State)                        | ery Adversa Events Following Innunization Community Court   | Type or Select (Defrict) |  | Type or Select (Vaccinetier                      | Certina)                         |                      |      |
| ients Registered Till Date                     | I Doses Administered Til Dat  |                          | Adverse Events Reported Till Date  | 0:   | Clients Fully Vaccinated wit     | h COVID-19 Till Date | 0    |
| 37346<br>0.5% since last week                  | 71418<br>+0.0% since last we  | rek                      | 12144<br>+2.0% since last week   |  | +0.0% since last w               | zek                  |      |
| ecentage of Infants Fully Vaccineted Fer State |   | 01                       |  | Ady Secondard S                                  | Prepart Terrer Adv Secondard S - | Ecostib 21 months    | 0    |
|  |   |                          | Pusie<br>Dom   | 2405   | 45425                            | #175                 |      |
|  | and the second se |                          | Datas<br>Dajant  | 4:5%   | 81345                            | epes                 | - 10 |
|  |   |                          | Tagashan .   | 5.825<br>5.825                                   | 48.42%                           | 61705<br>61805       |      |
|  | - A.  |                          | Kamataka<br>Wasi Bangai  | 5.305  |                                  | 40.005               | -    |
|  |   |                          | lati .   | 4345   | 62.005                           |                      |      |
|  |   |                          | Name of the Second Seco | 5.85%  | 51.005                           | 4.5%                 |      |
|  |   |                          | Tarvi Nada   | 2545   | \$3.25%                          |                      |      |
|  | State State State   | 4                        | Chandigarh<br>Morrain  | 2152%<br>81.07%                                  | 5.00%                            | 0.00%<br>0.00%       |      |
|  |   |                          | Muman<br>Jamma and Kaalmin   | 25.025   | 9.00%                            |                      | - 1  |
|  | and the second  |                          | Mathys Project   | 94,295   | 0.015                            | 0.005                |      |
|  |   |                          | Labelli<br>Accessed Desired  | 38.67%<br>33.32%                                 | 8.00%<br>9.00%                   | 6.00%<br>6.00%       |      |
|  |   |                          | Normana masan<br>Maripur   | 0.075  | 0.005                            | 0.005                | _    |
|  |   |                          | Laturationsp   | 45.00%<br>86.00%                                 | 5.00%<br>5.00%                   | 6.00%<br>6.00%       |      |
|  |   |                          | Anisaman and Nonliar Islands<br>Mighaines  | 0.00%  | 0.00%                            | 1275                 | - 1  |
|  |   |                          | Palathery  |  | 0.00%                            |                      |      |
|  | 1. A   | 1                        | Unavailable<br>Disc  | 0.005  | 6.00%                            | 6.00%<br>6.00%       |      |
|  |   | 1                        | Asses  |  | 0.00%                            | 0.075                |      |
|  |   |                          | Unit Probet  | 85.00%<br>25.07%                                 | 0.00%                            | 6.005<br>6.005       |      |
|  |   |                          | Justinei<br>Jim<br>Tala  | 10.10%<br>6.4%                                   | 6.005<br>60.005                  | 105                  | *    |
|  |   | ·                        | Tatala   | 6.4TK  | 43.545                           | 636                  |      |
|  |   |                          |  |  |                                  |                      |      |
|  |   |                          |  |  |                                  |                      |      |

Visualizations provide a high-level overview of key program indicators for vaccination programs

- Registrations
- Doses administered
- Adverse events reported
- Clients fully vaccinated


### Vaccine Delivery Analytics

| in term in te |  |  | ees Resolved by Clears 1<br>end aver  |  | In the second se   | A state of the |  | No Standards   | •••<br>••• |
|---|--|--|---|--|--|--|--|--|------------|
|   |  | An expension of the second   | ees Resolved by Clears 1<br>end aver  | 17 Aug<br>18 Aug Aug<br>18 Aug<br>19 | In the second se   | ne<br>Algenerates 107 di   |  | No Standards   | •••<br>••• |
| basement Market | based with the local data and th | Data Answerd 1920 0 1 200<br>711418  | ees Resolved by Clears 1<br>end aver  | 78 <b>box</b>  | In the second se   | 7.4y Nooloonat 1987 O  |  | No Standards   | •••<br>••• |
|   |  | 71418  | energies - in-<br>energies - inter-<br>tion - inter-<br>tion - inter-<br>energies - inter-<br>energ  | m,   | <ul> <li>Let</li> <li>Let</li></ul>  | 7.4y Nooloonat 1987 O  |  | No Standards   | •••<br>••• |
| 71418   | 71418  | Titlens  | ne Without I<br>see Status I and Status I<br>Status I<br>Status I and Status I<br>Status I<br>S  | 26   | <ul> <li>Let</li> <li>Let</li></ul>  | 7.4y Nooloonat 1987 O  |  |  | 01         |
|   |  | 71418  | anto-ling in a second s  | 26   | 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   | 7.4y Nooloonat 1987 O  |  |  | 01         |
|   |  | 71418  | is<br>produced the study<br>set 15-14 Add<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>memory<br>m  | 26   | <ul> <li>The second second</li></ul>   | 7.4y Nooloonat 1987 O  |  | 20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>2                  |            |
|   |  | Corporation interview<br>Corporation interview<br>Corporation interview<br>Corporation interview<br>Advanced in Corporation<br>Corporation interview<br>Advanced interview<br>Corporation interview | Y pounde houses<br>mini- Ana Car<br>Y<br>N<br>Second Second  | 26   | In the second se   | 7.4y Nooloonat 1987 O  | на н | vei<br>una<br>si<br>si<br>si<br>si<br>si<br>si<br>si<br>si<br>si<br>si<br>si<br>si<br>si         |            |
|   |  | ingeneration in the second sec   | eersis Audio (<br>normania)<br>annan marketain<br>annan marketa  | 26   | In the second se   | 7-by Noolmandt 1987 Of   |  | 60<br>80<br>80<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9<br>9   |            |
|   |  | transformed and the formation of the for   | nana mana mana mangangan mangangangan mangangangan mangangangan mangangangan mangangangangangan manganganganganganganganganganganganganga   | 26   | <ul> <li>Image: Comparison of the second second</li></ul>   | 7-by Noolmandt 1987 Of   |  | Vill<br>Pri<br>Pri<br>Pri<br>Pri<br>Pri<br>Ref   |            |
|   |  | any and a finite state of the s   | enes (Inputs)<br>and 1930 (<br>1930)<br>and 1930 (<br>1930)<br>and Science (<br>1930)<br>and Science (<br>1930)<br>and (<br>1930)<br>an | 26   | I Congress International Properties  | 7-by Noolmandt 1987 Of   |  | 6<br>6<br>7<br>7<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8<br>8 | •          |
|   |  | and and another state of the st   | enen fongtalis<br>en 1942<br>en 1942<br>en 1944 heren en 1944<br>internet en 1944<br>en 1944 heren en 1944<br>en 1944 heren en 1944 filt filt<br>heren en 1944 heren en 1944 filt filt<br>heren en 1944 heren en 1944 filt filt filt<br>heren en 1944 heren en 1944 filt filt filt filt filt filt filt filt   | 26   | Completely Introduced Impaired Ref   | 7-by Noolmandt 1987 Of   |  | i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i<br>i      | •          |
|   |  |  | eni Nilona Jonai<br>Nilona Jonai<br>Ann.<br>Ann Anna Stata Stata Stata<br>Anna Stata Stata Stata Stata<br>Anna Stata Stata Stata Stata  | 26   | In the second seco  | 7-by Noolmandt 1987 Of   |  | 200  | •          |
|   |  |  | eni Nilona Jonai<br>Nilona Jonai<br>Ann.<br>Ann Anna Stata Stata Stata<br>Anna Stata Stata Stata Stata<br>Anna Stata Stata Stata Stata  | 26   | en in  | 7-by Noolmandt 1987 Of   | 40<br>                                   | 200  | •          |
|   |  |  | eni filotos Jeneal<br>me<br>en<br>hothólynenusad 5314 503<br>hólynenusad  | 26   | I Completely Innuclease Response Title   | 7-by Noolmandt 1987 Of   |  | 200  | •          |
|   |  | angengi hananan datan<br>Angengi hananan datan<br>Angengi dagata haganan Angengina<br>Mangengi dagata haganan Angengina<br>Angengi dagata haganan Angengi dagata haganan Angengi dagata<br>Angengi dagata haganan Angengi dagata haganan Angengi dagata<br>Angengi dagata haganan Angengi dagata haganan Angengi dagata<br>Angengi dagata haganan Angengi dagata haganan Angengi dagata haganan Angengi dagata<br>Angengi dagata haganan Angengi dagata haganan Angengi dagata haganan Angengi dagata haganan Angengi dagata haganan<br>Angengi dagata haganan Angengi dagata hag  | nen<br>het het het het het het het het het het  | 26   | Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>Enter<br>En | 7-by Noolmandt 1987 Of   | 90° - <b>()</b> - <b>(</b> )             | 200  | •          |
|   |  |  | nothily herminal \$154.303<br>hothily herminal  | 26   | E Completely Innucleat Request No.   | 7-by Noolmandt 1987 Of   |  |  |            |
|   |  | 800  |   |  |  |  | aans O'Y O'Y O'S O'saan O'''saa          | n Dennend Copp. (77) Agence Log  |            |
|   |  |  |   |  |  |  |  |  |            |

Visualizations detailing vaccine service delivery and vaccination status

- Doses administered
- Immunization status (partial, fully)
- Clients due for follow up doses
- Vaccination drop off rates

### **Adverse Events Analytics**



Visualizations detailing adverse events following immunization

- Adverse events reported
- Side effects reported


### **Community Engagement Analytics**



Visualizations detailing community mobilization and counseling activities

- Events organized
- Participant types
- Presence of vaccine hesitancy
- Reported reasons for vaccine hesitancy

### **Stock Management Analytics**



Visualizations detailing stockouts and oversupply of vaccines, with the ability to view data at the facility level

- Stockouts reported
- Oversupply reported

# **Benchmarking Functionalities**

| Facilitates decision support for vaccine providers  | Yes   |
|---|---|
| Enables the scheduling of appointments, with validation checks to ensure follow up appointments are booked within appropriate timelines | No, but it can<br>integrate with 3rd<br>party tools that<br>assist with<br>scheduling |
| Captures reasons of refusal for vaccination, as well as access issues such as stock<br>outs   | Yes   |
| Facilitates patient monitoring and produces individual patient reports  | Yes   |
| Contains data on both vaccinated and unvaccinated individuals   | Yes, we can feed<br>data into a 3rd<br>party reporting tool                           |
| Displays aggregate data by geographic and/or administrative levels  | Yes, in a 3rd party<br>tool   |

# **Benchmarking Functionalities**

| Exchanges data through globally recognized standards such as FHIR   | Yes                                  |
|---|--------------------------------------|
| Produces or exports data consistent with that needed for microplanning  | No                                   |
| Produces data visualizations, such as charts and graphs, on vaccine coverage and other relevant program indicators      | Yes                                  |
| Captures Events Attributable to Vaccination and Immunization (EAVIs) or Adverse<br>Events Following Immunization (AEFI) | Yes                                  |
| Produces digitized, verifiable vaccine certificates   | Yes, a 3rd party tool generates them |
| Supports track and trace of vaccines via the use of standards such as GS1   | No                                   |

### Value-Add Features

Dimagi is developing CommCare apps to accompany the core solution

#### Wrap-around solutions include:

- Integration with Digital Vaccine Certificates
- Integration with Payments
- Integration with DHIS2
- RapidPro, Turn.io and Whatsapp Integrations for messaging
- EngageSPARK integration for interactive voice response (IVR) for automated direct-to-client calling
- Biometric scanning

Health worker registries, routine immunization registries, and health management information systems will support community-based engagement and turnkey integrations.



### **Hosting Options**

# SaaS

### Dimagi provides software and data storage

Benefit from Dimagi's 24-hour support, best-in-class security and regular platform upgrades. Partner can start collecting data immediately.

# Hybrid

Dimagi manages software, data archived in country

Data is moved from Dimagi's environment to server provided by the partner for longterm storage and / or analysis. Partner can start collecting data immediately.

- HIPAA, GDPR, ISO and SOC-2 security compliance provided by Dimagi
- Immediate platform access
- 24-hour support from Dimagi Support Team
- Recurring, predictable cost

- HIPAA, GDPR, ISO and SOC-2 security compliance provided by Dimagi
- Immediate platform access
- 24-hour support from Dimagi Support Team

# **On-Prem**

Partner manages hardware and software

Partner is responsible for setting up a data center, deploying CommCare HQ, releasing new versions, and ensuring system is on and available at all times. Start up time is variable and dependent upon partner.

- No security or up-time guarantees depends on team managing infrastructure
- 6-10 months until data collection can begin
- Personnel required to maintain system

# Implementation Support & Timelines

- Implementation approaches can be customized to meet the needs of partners.
- Options range from self-driven implementation to full implementation support
- Timelines are dictated by the level of implementation support and can range from 2 weeks to 18 months
- The Dimagi Vaccine Solution is designed to be quickly customized for more rapid roll-out, though this is still dependent on the level of adaptation needed



# **Contracting Options**

### SaaS

- Partners can independently adapt and deploy the Dimagi Vaccine Solution as a SaaS offering
- Implementation guides and onboarding offerings are available
- Simply pay a monthly hosting fee, which also includes Dimagi's standard support SLA

### Dimagi Services

- Partners can contract our Delivery team to provide hands-on program implementation support, including adapting the Dimagi Vaccine Solution
- Contract timelines are dependent on the support needed

# **Cost Considerations**

The cost to set-up and maintain the Dimagi Vaccine Solution or other CommCare mobile application is driven by the implementation model, as well as the complexity of the application

### SaaS

- For the Dimagi Vaccine Solution, partners pay a subscription fee of \$1200 per month, which includes a CommCareHQ project space, 500 mobile workers, and access to Dimagi Standard Support SLA
- Onboarding packages are also available and range from \$1,500 to \$7,500.

### Dimagi Services

- Partners can contract our Delivery team to provide hands-on program implementation support, including adapting the Dimagi Vaccine Solution
- Partners will pay the monthly hosting fee, as well as the cost of Dimagi's time.
- Additional costs may include the integrations, messaging, etc.





Utilizing CommCare for Vaccine Administration in Jamaica





In March 2021, Jamaica became the first Caribbean country to receive a shipment of COVAXprocured vaccines.

The Ministry of Health and Wellness (MOHW), UNICEF, the Private Sector Vaccine Initiative (PSVI) and Dimagi joined efforts to combat the spread of the virus through the rapid deployment of CommCare.

### Covid19 Impact and What Did We Do?



- ✓ COVID19 affected the socio-economic situations in Jamaica
- ✓ Government approved Vaccine Deployment and Vaccination Interim Plan
- Established Vaccination Management Task Force comprising of 6 workstreams
- ✓ Appointed ICT expert as chairman of the information systems work stream to establish a digital platform for the vaccine roll-out
- ✓ Jamaica's COVID-19 implementation programme got underway

### Engagement with the Private Sector

The Private Sector Vaccine Initiative is a mechanism to support Jamaica's COVID-19 vaccination efforts.



# **#GetTheFacts. #GetTheVax.**

The PSVI encourages every Jamaican to get the right information about COVID-19 vaccines and get vaccinated at the first opportunity.



# CommCare & COVID-19 Vaccine Delivery

In 2020, Dimagi developed a solution to capture vaccination details and equitable distribution of COVID-19 vaccines.

The solution is currently used at **national scale in multiple countries** with **over 1.4 million vaccine doses tracked** in Jamaica.



- Launched in May 2021
- 1,496,493 doses recorded (by October 20, 2022)
- The CommCare mobile application was deployed in over 150 vaccination sites with 2,000+ users
- Superset reporting dashboard
- Digital COVID-19 certificate launched in December 2021
- Trained 150+ trainer of trainers
- Implemented change management and adoption of the digital tools






### Jamaica Timeline

COVID-19 Vaccine Monitoring Discussions and Implementation (Feb to May 2021)



# **Deployed Architecture**



# MoHW User: Workflows



# Screening Vaccination Follow up Q Certificate

Register clients Screen for eligibility Maintain waitlist

Record dose delivery Schedule next dose Track Course Completion

Record adverse events Lost to follow up tracking

Electronic COVID-19 vaccine certificate

### **Implementation Challenges**

- Lower digital literacy across the health workforce
- Resistance to the adoption of technology
- Nascent digital health architecture and HIS
- Low level of internet connectivity across the island



Alignment of stakeholders across autonomous health regions

Pressure to deploy quickly



### **Training Strategy**

A training-of-trainers model ensured **150 master trainers** were equipped with the knowledge and skills to train more than **1,000 healthcare workers** across the island, including medical officers, primary **healthcare nurses**, **medical records officers**, and **information technology officers**.

**Capacity building sessions** with the MOHW were conducted on trouble-shooting within CommCare.



# MoHW User: Register Client

- Register clients
- Screen for eligibility
- Maintain waitlist

\* Please select the vaccination site at which this ABC Health Services x - 🖌 beneficiary was vaccinated Combobox Client Demographic Information \* First name Free response Middle Name Free response \* Last name Free response The reference number for the client is COXNGFT. Please ask them to note down the reference number for future follow ups with the facility. Date of birth details \* Date of birth Ê

Male
 Female

\* Gender

#### Screening

# MoHW User: Screening

- Register clients
- Screen for eligibility
- Maintain waitlist

#### Screening



| Clinical Questions                                      |               |                            |                    |          |                 |
|---|---------------|----------------------------|--------------------|----------|-----------------|
| Bleeding disorder or on blood thinners                  | Yes           |                            | ~                  |          |                 |
|   | O No          |                            |                    |          |                 |
|   |               |                            | Clear              |          |                 |
| Recent vaccine in last 2 weeks                          | Yes           |                            | ~                  |          |                 |
|   | O No          |                            |                    |          |                 |
|   |               |                            | Clear              |          |                 |
| Have you ever had an allergic reaction to a<br>vaccine? | Yes           |                            | ~                  |          |                 |
|   | O No          |                            | Clear              |          |                 |
| Describe the reaction                                   |               |                            |                    |          |                 |
| Describe the reaction                                   |               |                            | h                  |          |                 |
|   | Free response |                            |                    |          |                 |
| Is this person for vaccination?                         | O Yes         |                            |                    |          |                 |
|   | O No          |                            |                    |          |                 |
| Is there any other reason this person might not         | Yes           |                            | ~                  |          |                 |
| want to be vaccinated?                                  | O No          |                            |                    |          |                 |
|   |               |                            | Clear              |          |                 |
| Please describe   |               |                            |                    |          |                 |
|   |               |                            | 4                  |          |                 |
|   |               | Case Detail                |                    |          |                 |
|   |               | CLIENT DEMOGRAPHICS        | OTHER DETAILS      | CLINICAL | COMORBIDITIES   |
|   |               | VACCINATION DETAILS        | PAST COVID DETAILS | REPORT   | ED SIDE EFFECTS |
|   |               | Diabetes-Mellitus          |                    |          | Not Specified   |
|   |               | Hypertension               |                    |          | Not Specified   |
|   |               | Cancer                     |                    |          | Not Specified   |
|   |               | Heart Condition            |                    |          | Not Specified   |
|   |               | Asthma                     |                    |          | Not Specified   |
|   |               | Chronic Lung Disease Non A | Asthma             |          | Not Specified   |
|   |               | Sickle Cell Disease        |                    |          | Not Specified   |
|   |               | Vascular Disease           |                    |          | Not Specified   |
|   |               | Other Comorbidities        |                    |          | Not Specified   |

Continue

# MoHW User: Maintain Waitlist

- Register clients
- Screen for eligibility
- Maintain waitlist

| NAME            | CLIENT ID | DATE OF REGISTRATION                        |  |
|-----------------|-----------|---|--|
| List is empty.  |           |   |  |
| Register Client | ]         |   |  |
|                 |           | Formplayer Version: 2.53, App Version: 2233 |  |
|                 |           |   |  |
|                 |           |   |  |

COVID-19 Vaccine Test App > Waiting List

WAITING LIST

#### Screening

## MoHW User: Vaccination

- Record dose delivery
- Schedule next dose
- Track Course

#### Vaccination



#### COVID-19 VACCINE DELIVERY







#### All Registered Clients

Lost to Follow Up

Eligible

Waiting List



Mid-Course

My Information





| Select the type of vaccine  | Astra Zeneca | × * | ~ |
|---|--------------|-----|---|
|   | Combobox     |     |   |
| * Vaccine Batch Number:   | ABZ6077      | ××  | ~ |
|   | Combobox     |     |   |
| Vaccine batch: ABZ6077     Manufacture:: AstraZeneca AB     Vaccine expiration date: 2021-11-30 |              |     |   |
| Dose Details  |              |     |   |
| Dose Astra Zeneca Dose 1 details:   |              |     |   |
| <ul> <li>Type of Vaccine: Astra Zeneca</li> </ul>   |              |     |   |
| Dose No: 1  |              |     |   |
| <ul> <li>Date of dose : 2020-01-28</li> </ul>   |              |     |   |

If you are entering backlog data, would you like O Yes to enter the confirmed second dose appointment date? (If the second dose appointment has not Vet been confirmed, select No.)

# MoHW User: Follow up

- Record adverse
   events
- Lost to follow up tracking

| LOST TO FOLLOW UP |           | Click h    | ound color<br>ere and then select a color from the color<br>This color is used with the eraser and<br>pe fills. |                     |
|-------------------|-----------|------------|---|---------------------|
| Search            |           |            |   |                     |
|                   |           | DOB        | DAYS SINCE MISSED FOLLOW-UP   |                     |
| NAME              | CLIENT ID | DOB        | DATS SINCE MISSED FOLLOW-UP   | CLIENT FOLLOWED UP? |
| NAME              |           | 2004-01-01 | 71  | No                  |


#### Follow up

# MoHW User: Certificate

- Produce COVID-19
   vaccine certificate
- Search COVID-19
   vaccine certificate
- Print COVID-19 vaccine certificate

Certificate





### Limitations and Technical Challenges > Learning and Evolving

CommCare needed to be configured for clients seeking second doses from different facilities

Workflow version changes were initially slow to sync with mobile apps, requiring manual synching

Rapid bulk data entry to reduce the backlog of paper records resulted in data entry errors

Unanticipated changes in health policy, such as the mixing of vaccines, created the need for workflow configuration changes



### **Promising Next Steps**

- Health workers originally resistant to technology are now welcoming the digitization of additional programs.
- Landscaping readiness assessment being planned for the digitization of routine immunization activities.



## Enabling factors and necessary parallel investments

- ICT infrastructure (electricity, internet, hardware)
- Financial (long-term sustainability and maintenance costs)
- Social and political (change management/training of health staff, verifiable commitment from the authorities, legal frameworks)
- Program management requirements (processes in place to take action based on data)



### From this....



### ....to this!

Digital Health Centre of Excellence



World Health Organization



